RxDoctor Payments Data

Sareena Singh, MD

Gynecologic Oncology · St Petersburg, FLNPI 1326205303

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $34,040 of the $53,572 with a category attached, or 63.5%. 29 manufacturers reported payments, led by AstraZeneca at 47.1% of the total. Reporting peaked in 2019 at $13,854 and has fallen 69.9% since, to $4,168 in 2025.

$53,572in general payments, 2019–2025

Across 217 payments — averaging $246.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$25K
  • Merck$17K
  • Pfizer$4K
  • Intuitive Surgical$4K
  • Tesaro, Inc.$448
  • Johnson & Johnson$289
  • plus $2K from 23 others
$1,055,450in research payments, 2019–2025

Across 55 payments — averaging $19,190 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$439K
  • Tesaro, Inc.$405K
  • Merck$189K
  • E.r. Squibb & Sons, L.L.C.$22K
  • Bristol Myers Squibb$1K

What the payments were for

  • Consulting fees$4,2948%
  • Speaking & faculty fees$34,04064%
  • Travel & lodging$6,67912%
  • Food & beverage$5,32310%
  • Education$3,2366%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,572 in reported general payments places this provider in the 85th percentile of 117 gynecologic oncology providers in Florida.

See all gynecologic oncology providers in Florida

Medicare billing

Part B allowed, 2024
$34,319
Medicare patients
60
Services billed
181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dexamethasone22$417
Oxycodone Hcl25$268
Ondansetron Hcl16$187
Letrozole12$106
Olanzapine11$97

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →